Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises, Inc. (NUS) reported that director Edwina D. Woodbury acquired 22 shares of Class A Common Stock on September 9, 2026 through a grant or award transaction. The shares were credited at an effective price of $4.85 per share via dividend reinvestment under the company’s Deferred Compensation Plan.
After this acquisition, Ms. Woodbury directly holds a total of 62,474 shares of Nu Skin Class A Common Stock. No transactions were reported as made under a Rule 10b5-1 trading plan.
Nu Skin Enterprises, Inc. (NUS) reported that Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026. During his absence, Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark will lead Mr. Keisel’s organization.
The company expresses support for Mr. Keisel as he focuses on his health. No changes to other executive roles or broader strategic initiatives are described in this report.
Nu Skin Enterprises reported significantly weaker results for the quarter and six months ended June 30, 2026. Revenue fell 17.1% to $320.1 million in the quarter and 14.6% to $640.7 million year-to-date, driven by broad-based declines across all Nu Skin geographies and both Rhyz segments, as macroeconomic pressures reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8%, and Sales Leaders 9% year over year.
Profitability deteriorated sharply. The company recorded an operating loss of $59.3 million for the quarter and a net loss of $249.8 million, versus net income of $21.1 million a year earlier. For the first half, net loss was $248.0 million, compared to $128.6 million in 2025. Results were heavily impacted by a $78.9 million goodwill impairment in the Manufacturing segment and a $167.5 million valuation allowance against U.S. deferred tax assets, producing an effective tax rate of (295.4)% for the quarter. Diluted EPS swung to $(5.14) for the quarter and $(5.12) year-to-date, versus $0.43 and $2.59, respectively.
Despite the downturn, gross margin remained high at 68.2% for the quarter. Operating cash flow was positive but modest at $6.7 million for the first half, while cash and cash equivalents decreased to $189.6 million from $238.6 million at year-end 2025. The company refinanced its credit facilities with a new $175 million term loan and $75 million revolver and reported compliance with leverage and interest coverage covenants. Nu Skin continued paying quarterly dividends of $0.06 per share and repurchased 0.5 million shares for $5.0 million in the first half.
Nu Skin Enterprises reported weak second-quarter 2026 results heavily affected by non-cash charges. Revenue was $320.1 million, down 17.1% from $386.1 million, with a 1.0% FX headwind. Customers declined 14% to 660,037, Paid Affiliates fell 8%, and Sales Leaders decreased 9%, indicating broad-based volume pressure across regions.
GAAP diluted EPS was a loss of $(5.14), driven largely by a $78.9 million impairment charge and a substantial valuation allowance on deferred tax assets, producing an effective tax rate of (295.4)%. On a non-GAAP basis, EPS was $0.20, versus $0.43 a year earlier, and operating margin was 6.1% excluding impairment, compared with 8.0%.
For full-year 2026, the company now guides revenue to $1.28–$1.35 billion, a 14%–9% decline, and GAAP EPS of $(4.90)–$(4.73), or $0.70–$0.90 on an adjusted basis. Q3 2026 revenue is expected at $310–$340 million with adjusted EPS of $0.10–$0.20, while management continues rolling out the Prysm iO platform and preparing for an India launch.
NU SKIN ENTERPRISES, INC. director Edwina D. Woodbury acquired 19 shares of Class A Common Stock at $5.43 per share through a dividend reinvestment under the Company's Deferred Compensation Plan. Following this plan-related award, she directly holds 62,452 shares of Class A Common Stock.
Nu Skin Enterprises director James M. Winett reported both an equity grant and a sale of Class A Common Stock. On June 1, 2026, he acquired 26,643 shares as a grant at $0.00 per share. On June 2, 2026, he executed an open-market sale of 7,203 shares at $5.62 per share pursuant to a Rule 10b5-1(c) trading plan adopted on November 11, 2025. After these transactions, he directly holds 37,448 shares of Nu Skin’s Class A Common Stock, indicating he retained a substantial position following the sale.
Nathanson Laura reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Laura Nathanson received a grant of 26,643 shares of Class A Common Stock on June 1, 2026. The shares were awarded at no purchase price, increasing her directly held stake to 57,116 shares after the transaction. This reflects compensation in equity rather than a market purchase.
Zorko Mark A reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Mark A. Zorko received a grant of 26,643 shares of Class A Common Stock on June 1, 2026 at no purchase price. Following this equity award, he directly holds 60,586 shares. This is a compensation-related grant, not an open-market trade.
NU SKIN ENTERPRISES, INC. director Edwina D. Woodbury reported both a sale and a stock grant of Class A Common Stock. On June 1, 2026, she executed an open-market sale of 7,203 shares at $5.70 per share. The same day, she acquired 26,643 shares through a grant or award at no stated purchase price. Following these transactions, her direct holdings totaled 62,433 shares of Class A Common Stock. The footnote states the sale occurred under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) adopted on February 19, 2026, indicating the sale’s timing was planned in advance.
NU SKIN ENTERPRISES, INC. director Emma S. Battle received a grant of Class A Common Stock as equity compensation. She acquired 26,643 shares at a stated price of $0.0000 per share, increasing her direct holdings to 57,648 shares of Class A Common Stock following the transaction.